drugset
Drugs / VB15010
last change Mar 2026 re-read 3 minutes ago

VB15010

targets PARP1 via inhibition

Developed for
biliary tract cancer · breast cancer · colorectal cancer · malignant pancreatic neoplasm · ovarian neoplasm · prostate cancer
Investigated by
Shandong Cancer Hospital and Institute · Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Trials 1

today NCT06819215 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06819215 Oct 2024 → Dec 2025 overdue biliary tract cancer, breast cancer, colorectal cancer, malignant pancreatic neoplasm +2 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VB15010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06819215 ↗
Action Inhibit “Oral PARP1 inhibitor” NCT06819215 ↗
Route Oral “Oral PARP1 inhibitor” NCT06819215 ↗
Target PARP1 “Oral PARP1 inhibitor” NCT06819215 ↗